Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.43 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529581 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30743365 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL26783267 | 1.00 | ALOX5AP (0.47) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29529911 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL24399166 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL23605880 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29508261 | 0.94 | GPR119 (0.43) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22602644 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22602678 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL29102386 | 0.86 | ALOX5AP (0.48) | ALOX5APFEN1CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230121818-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4081514-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021133894-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021133894-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121818-A1 | BTK INHIBITORS | BTK, SYK, LYN | ALOX5AP 4471/4885FEN1 3710/4885CHRNB2 3434/4885 |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | ALOX5AP 4081/4885FEN1 3459/4885CHRNB2 2813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.